Syncromune's SYNC-T Therapy Shows Bone Metastases Resolution in Phase 1 Prostate Cancer Trial
Key Insights
Syncromune (search)'s Phase 1 study of SYNC-T Therapy SV-102 (search) demonstrated radiographic resolution of bone metastases (search) in metastatic prostate cancer (search) patients who achieved complete responses.
The abstract was selected as one of the "Top 30" submissions at the Society of Urologic Oncology's 26th Annual Meeting, recognizing it among the highest scoring abstracts of the year.
SYNC-T (search) is an in situ personalized combination immunotherapy platform that synchronizes tumor lysis, antigen release, and targeted drug delivery to activate T-cell responses against cancer.
Syncromune (search), Inc. announced promising Phase 1 results for its SYNC-T Therapy SV-102 (search), demonstrating radiographic resolution of bone metastases (search) in metastatic prostate cancer (search) patients who achieved complete responses. The clinical-stage biopharmaceutical company's abstract was selected as one of the "Top 30" submissions at the Society of Urologic Oncology (SUO) 26th Annual Meeting, scheduled for December 2-5, 2025 in Phoenix, Arizona.
Novel Immunotherapy Platform Shows Clinical Promise
The now-concluded Phase 1 study focused on SYNC-T Therapy SV-102 (search)'s ability to address bone metastases (search), which represent one of the most significant drivers of morbidity and mortality in advanced prostate cancer. The data will be presented by Gerald Andriole, M.D., as Poster 175 during the SUO Top Abstract Tour on December 4, 2025.
SYNC-T (search) represents a potentially first-in-class platform immunotherapy designed to address major unmet medical needs in incurable metastatic solid tumor cancers (search). The therapy is engineered as an in situ personalized cancer treatment that synchronizes three critical components for T cell (search) activation and anti-tumor immune response.
Innovative Drug Delivery Mechanism
The SYNC-T (search) system features a novel proprietary needle-like device delivery system optimized for combination drug/device immunotherapy. The mechanism operates through a two-step process: first, the system lyses a portion of a target tumor to rupture tumor cells and release patient-specific tumor antigens into the tumor microenvironment (TME), helping to activate the immune system. Subsequently, the delivery system facilitates the infusion of Syncromune (search)'s proprietary multi-target biologic drug directly into the lysed tumor area.
This location synchronization approach is designed to unite patient-specific tumor antigens, immune modulators, and the multi-target biologic drug together in the draining lymphatics where the immune system optimally functions. The combination therapy targets numerous cancer mechanisms, promoting in situ immune activation while battling immune suppression and minimizing systemic drug exposure.
Advancing to Phase 2 Development
The therapy's goal is to educate the immune system and activate T cells that can recognize and attack cancer throughout the body while providing immune memory defense. Syncromune (search)'s lead candidate, SYNC-T Therapy SV-102 (search) for metastatic castration-resistant prostate cancer (search) (mCRPC), is currently being evaluated in the LEGION-100 U.S., multicenter, Phase 2 trial.
The recognition as a "Top 30" abstract at the SUO meeting underscores the potential clinical significance of SYNC-T (search)'s approach to treating advanced prostate cancer, particularly its ability to address the challenging complication of bone metastases (search) that significantly impacts patient outcomes in this population.